RxDoctor Payments Data

Abraham Parail, MD

Interventional Cardiology · Gahanna, OHNPI 1073551909

Payments from drug & device makers

$8,887in general payments, 2019–2025

Across 151 payments — averaging $58.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abbott$1K
  • W. L. Gore & Associates, Inc.$1K
  • Abiomed$902
  • Medtronic$886
  • Edwards Lifesciences$793
  • plus $891 from 16 others

What the payments were for

  • Consulting fees$1,87521%
  • Travel & lodging$2,00323%
  • Food & beverage$5,00856%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,887 in reported general payments places this provider in the 55th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$100,074
Medicare patients
505
Services billed
726

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$305,614
EntrestoSacubitril/Valsartan147$173,449
XareltoRivaroxaban89$100,051
Repatha SureclickEvolocumab66$69,333
JardianceEmpagliflozin19$23,255
OzempicSemaglutide11$15,789
Praluent PenAlirocumab14$7,623
Metoprolol Succinate462$6,228
Ranolazine ErRanolazine49$6,172
Atorvastatin Calcium349$3,410
Prasugrel Hcl15$3,147
ClopidogrelClopidogrel Bisulfate224$2,876
Rosuvastatin Calcium208$2,302
Ezetimibe115$1,464
Losartan Potassium162$1,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$305,614280 claims
NovartisEntresto$92$173,449147 claims
Johnson & JohnsonXarelto$15$100,05189 claims
Novo NordiskOzempic$57$15,78911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Gahanna

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →